Rhelion Life Sciences Corp.RHEL.CN
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · CSE · Canada · redlight.co
Legal-psychedelics company selling psilocybin truffles and grow kits in the Netherlands and, via its April 2026 acquisition of Filament Health Corp., developing pharmaceutical-grade natural psilocybin drug candidates led by PEX010. A rename to Rhelion Life Sciences Corp is pending CSE approval.
Key ratios
FCF / Sales
-64.4%TTM
2025
-40.7%2024
-82.5%2023
-163.3%
Net margin
-119.2%TTM
2025
-81.8%2024
-160.5%2023
-136.7%
ROA
-13.6%TTM
2025
-11.6%2024
-14.3%2023
-9.8%
ROE
-31.4%TTM
2025
-22.9%2024
-33.1%2023
-20.9%
Revenue growth
4.1%2025
2024
20.3%2023
69.8%
Recent news
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010
Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness Therapy
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate
Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program
Rhelion Life Sciences Reports First Quarter 2027 Results
Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and Depression
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee® AI Platform in Early Alzheimer's Disease Trial Design
Rhelion Life Sciences Announces Appointment of Samiuddin Khaja as CFO
Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression
Track RHEL.CN in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer